Sanjivani Paranteral Q1 FY27 Share Price & Earnings Call Analysis

₹166.80+0.82% today
Market cap
₹205 Cr
P/E
20.55
ROE
15.73%
Price to sales
2.43
Debt to equity
0.30
52W high / low
₹240 / ₹129
EBITDA margin
19.02%
Net profit margin
9.87%
Promoter holding
31.56%
Sales (last year)
₹84 Cr

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]

Guidance scorecard · Q1 FY27 call

What Sanjivani Paranteral's management guided
and where it ranks in Pharmaceuticals & Biotechnology

RevenueQ3 FY26 call

10–20%
  • FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
  • SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
  • Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
  • Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
  • Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
  • Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
  • Export markets to continue being key revenue drivers, contributing ~77% of total revenue.

2 more points from Sanjivani Paranteral's call on revenue

Create a free account to keep reading this call

Full Q3 FY26 analysis

MarginsQ3 FY26 call

Flat

See what Sanjivani Paranteral said on margins — free account, 30 seconds.

Full Q3 FY26 analysis

CapexQ3 FY26 call

Planned
  • Major capex cycle is currently over; all plants are operational.
  • FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
  • No significant new capex expected in FY '27 beyond this recurring amount.
  • Future growth is expected from ramp-up and approvals rather than large new investments.

2 more points from Sanjivani Paranteral's call on capex

Create a free account to keep reading this call

Full Q3 FY26 analysis

FundraisingQ3 FY26 call

Planned

See what Sanjivani Paranteral said on fundraising — free account, 30 seconds.

Full Q3 FY26 analysis

Order bookQ3 FY26 call

  • It indicates strong growth driven primarily by export markets and product mix improvements.
  • The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
  • The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
  • Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28.
Full Q3 FY26 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Sanjivani Paranteral latest results (Mar 2026)

Revenue

₹11 Cr

-42% YoY

Net profit

₹1 Cr

-57% YoY

Operating margin

8.66%

EPS

₹0.77

What management said on the call →

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,142 Cr34.2
240%+Up 2%+₹489 Cr16.7
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,464 Cr1614.0
540%+Flat₹9,050 Cr34.8
640%+Flat₹4,493 Cr—

Sign up free to see every company in the sector ranking and track Sanjivani Paranteral.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Sanjivani Paranteral

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Sanjivani Paranteral

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +8.1212.5814.0014.9612.8616.4418.1317.3518.1817.8915.5020.8610.51
Expenses +6.6910.5711.8812.9910.7014.1015.2814.8015.5715.2513.2517.269.60
Operating Profit1.432.012.121.972.162.342.852.552.612.642.253.600.91
OPM %17.61%15.98%15.14%13.17%16.80%14.23%15.72%14.70%14.36%14.76%14.52%17.26%8.66%
Other Income +-0.040.060.150.250.050.090.390.310.430.040.160.290.75
Interest0.160.040.050.080.090.020.180.190.200.220.050.210.06
Depreciation0.230.230.230.240.240.130.150.160.180.160.170.190.35
Profit before tax1.001.801.991.901.882.282.912.512.662.302.193.491.25
Tax %0.00%13.89%14.07%13.16%33.51%24.56%21.31%24.30%17.29%24.78%25.11%24.93%25.60%
Net Profit +1.001.551.711.651.261.712.301.902.191.731.642.620.94
EPS in Rs1.001.551.711.651.081.461.971.601.841.431.342.130.77

Financials of Sanjivani Paranteral

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +133.03115.3132.5317.9625.0916.2925.0930.5941.4554.4170.1064.76
Expenses +127.71120.8455.8170.1726.8516.6222.9524.8635.8046.1859.7455.36
Operating Profit5.32-5.53-23.28-52.21-1.76-0.332.145.735.658.2310.369.40
OPM %4.00%-4.80%-71.56%-290.70%-7.01%-2.03%8.53%18.73%13.63%15.13%14.78%14.52%
Other Income +1.240.732.850.480.960.250.260.240.540.521.211.24
Interest7.928.814.790.450.330.660.130.210.360.250.590.54
Depreciation1.411.361.201.191.171.070.860.880.890.930.620.86
Profit before tax-2.77-14.97-26.42-53.37-2.30-1.811.414.884.947.5710.369.24
Tax %-13.00%-2.20%-0.72%-0.60%-10.00%-5.52%-0.71%0.61%8.70%18.63%21.81%25.00%
Net Profit +-2.41-14.64-26.22-53.06-2.07-1.711.424.854.516.178.106.92
EPS in Rs-4.09-24.82-44.45-89.96-3.51-2.901.674.854.515.286.825.63
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%7.33%0.00%

Financials of Sanjivani Paranteral

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital5.905.905.905.905.905.908.5010.0010.0011.6811.8812.28
Reserves26.2411.60-14.62-58.72-53.10-54.81-53.39-17.58-13.0716.2226.1232.55
Borrowings +57.0662.2059.8948.2348.0948.9146.056.002.490.975.626.70
Other Liabilities +24.4813.429.1529.6117.0915.6618.1119.8721.5914.5321.376.85
Total Liabilities113.6893.1260.3225.0217.9815.6619.2718.2921.0143.4064.9958.38
Fixed Assets +13.5212.6911.1910.178.998.047.627.427.579.9420.5621.28
CWIP0.010.000.000.000.000.000.000.000.000.000.000.00
Investments0.050.050.050.050.050.050.050.050.050.003.003.91
Other Assets +100.1080.3849.0814.808.947.5711.6010.8213.3933.4641.4333.19
Total Assets113.6893.1260.3225.0217.9815.6619.2718.2921.0143.4064.9958.38

Financials of Sanjivani Paranteral

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-1.200.459.573.052.48-0.170.588.524.68-10.70-0.24-1.55
Cash from Investing Activity +8.68-0.500.30-0.200.02-0.12-0.42-0.67-0.99-12.21-5.81-4.47
Cash from Financing Activity +-7.30-0.51-10.05-2.83-2.300.33-0.26-7.68-3.7323.166.146.54
Net Cash Flow0.18-0.57-0.180.030.200.03-0.090.17-0.040.240.090.52
Free Cash Flow7.47-0.069.872.852.50-0.300.157.843.63-14.00-11.48-5.21
CFO/OP-23%-8%-41%-6%-143%48%28%150%84%-117%10%6%

Financials of Sanjivani Paranteral

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days184.24151.59358.38107.7175.7923.9796.4558.7117.5231.5386.85
Inventory Days68.5965.35127.4134.0813.5666.8022.4351.89105.21124.7093.96
Days Payable37.5019.5142.51169.13292.82434.62261.00339.20269.8273.56137.51
Cash Conversion Cycle215.34197.43443.28-27.33-203.47-343.84-142.12-228.61-147.0882.6743.30
Working Capital Days61.3826.72-196.58-1,285.22-714.43-1,162.44-707.31-173.01-129.2735.5583.73
ROCE %5.95%-7.31%-35.52%-227.18%-258.43%265.52%55.28%30.21%

Guidance history

How Sanjivani Paranteral's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q3 FY26 call →10–20%FlatPlannedPlanned—
Q2 FY26 call →10–20%FlatPlannedPlannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

Sanjivani Paranteral: frequently asked questions

What is Sanjivani Paranteral share price today?

Sanjivani Paranteral last traded at ₹166.8, with a market capitalisation of ₹205 Cr and a P/E ratio of 20.6.

What were Sanjivani Paranteral's latest quarterly results?

For the quarter ended Mar 2026, Sanjivani Paranteral reported revenue of ₹11 Cr (-42% year on year) and net profit of ₹1 Cr, with an operating margin of 8.66%.

Is Sanjivani Paranteral's profit growing?

Net profit was ₹1 Cr in Mar 2026 against ₹2 Cr in Mar 2025, a change of -57%.

What is Sanjivani Paranteral's EPS?

Sanjivani Paranteral's earnings per share for the quarter ended Mar 2026 was ₹0.77.

What is Sanjivani Paranteral's ROE and ROCE?

Sanjivani Paranteral's return on equity is 18.2% and its return on capital employed is 22.4%.

Does Sanjivani Paranteral pay a dividend?

Yes. Sanjivani Paranteral's dividend yield is 0.32% at the current price. The full payout history is on the Sanjivani Paranteral dividends page.

Which sector does Sanjivani Paranteral belong to?

Sanjivani Paranteral is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Sanjivani Paranteral's management say on the latest earnings call?

Arthneeti's analysis of the Q1 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Sanjivani Paranteral's management.

How does Arthneeti AI analyse Sanjivani Paranteral?

Arthneeti reads Sanjivani Paranteral's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem